TipRanks
Faeth Therapeutics (FTH)
NASDAQ:FTH
US Market
FTH
Faeth Therapeutics
RESEARCH TOOLSreports
Want to see FTH full AI Analyst Report?

Faeth Therapeutics (FTH) Stock Forecast & Price Target

255 Followers
See the Price Targets and Ratings of:

FTH Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Faeth
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FTH Stock 12 Month Forecast

Average Price Target

$57.64
▲(74.81% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Faeth Therapeutics in the last 3 months. The average price target is $57.64 with a high forecast of $70.00 and a low forecast of $51.00. The average price target represents a 74.81% change from the last price of $32.97.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","71":"$71","22.25":"$22.3","38.5":"$38.5","54.75":"$54.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.63636363636363,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$51.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,22.25,38.5,54.75,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.51,37.239999999999995,39.97,42.699999999999996,45.43,48.16,50.89,53.62,56.349999999999994,59.08,61.81,64.53999999999999,67.27,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.51,36.28895104895105,38.0679020979021,39.84685314685314,41.62580419580419,43.40475524475524,45.183706293706294,46.96265734265734,48.74160839160839,50.52055944055944,52.29951048951049,54.07846153846154,55.85741258741258,{"y":57.63636363636363,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.51,35.778461538461535,37.04692307692307,38.315384615384616,39.58384615384615,40.85230769230769,42.12076923076923,43.389230769230764,44.65769230769231,45.926153846153845,47.19461538461538,48.463076923076926,49.73153846153846,{"y":51,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.67,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.81,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":34.79,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":26.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.66,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.51,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$57.64Lowest Price Target$51.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on FTH
Bradley Canino
Guggenheim
Guggenheim
$70
Buy
112.31%
Upside
Initiated
09/15/26
Faeth Therapeutics initiated with a Buy at GuggenheimFaeth Therapeutics initiated with a Buy at Guggenheim
Lucid Capital Analyst forecast on FTH
Dev Prasad
Lucid Capital
Lucid Capital
$59
Buy
78.95%
Upside
Initiated
09/14/26
Faeth Therapeutics assumed with a Buy at Lucid CapitalFaeth Therapeutics assumed with a Buy at Lucid Capital
BTIG Analyst forecast on FTH
Jeet Mukherjee
BTIG
BTIG
$55
Buy
66.82%
Upside
Reiterated
09/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on FTH
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Initiated
09/09/26
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH) and Novartis (NYSE: NVS)
Needham Analyst forecast on FTH
Gil Blum
Needham
Needham
$56
Buy
69.85%
Upside
Initiated
08/21/26
Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target
H.C. Wainwright Analyst forecast on FTH
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$60
Buy
81.98%
Upside
Reiterated
08/11/26
Analyst Reiterates Buy on Faeth, Maintains $60 Price Target Ahead of Phase 2 Readouts
Oppenheimer Analyst forecast on FTH
Jay Olson
Oppenheimer
Oppenheimer
$60
Buy
81.98%
Upside
Reiterated
08/05/26
Oppenheimer Keeps Their Buy Rating on Faeth Therapeutics (FTH)
JonesTrading Analyst forecast on FTH
Boris Peaker
JonesTrading
JonesTrading
$55
Buy
66.82%
Upside
Initiated
08/04/26
Faeth Therapeutics initiated with a Buy at JonesResearchFaeth Therapeutics initiated with a Buy at JonesResearch
Raymond James Analyst forecast on FTH
Sean McCutcheon
Raymond James
Raymond James
$56
Buy
69.85%
Upside
Initiated
07/31/26
Faeth Therapeutics initiated with an Outperform at Raymond JamesFaeth Therapeutics initiated with an Outperform at Raymond James
Citizens JMP Analyst forecast on FTH
Silvan Turkcan
Citizens JMP
Citizens JMP
$51
Buy
54.69%
Upside
Initiated
07/20/26
Faeth Therapeutics initiated with an Outperform at CitizensFaeth Therapeutics initiated with an Outperform at Citizens
Citi Analyst forecast on FTH
Geoff Meacham
Citi
Citi
$55
Buy
66.82%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Staar Surgical (NASDAQ: STAA), Intuitive Surgical (NASDAQ: ISRG) and Faeth Therapeutics (NASDAQ: FTH)
Robert W. Baird Analyst forecast on FTH
Jack Allen
Robert W. Baird
Robert W. Baird
$57
Buy
72.88%
Upside
Initiated
06/26/26
Faeth Therapeutics initiated with an Outperform at BairdFaeth Therapeutics initiated with an Outperform at Baird
Cantor Fitzgerald Analyst forecast on FTH
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (NASDAQ: SNSE) and Kura Oncology (NASDAQ: KURA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on FTH
Bradley Canino
Guggenheim
Guggenheim
$70
Buy
112.31%
Upside
Initiated
09/15/26
Faeth Therapeutics initiated with a Buy at GuggenheimFaeth Therapeutics initiated with a Buy at Guggenheim
Lucid Capital Analyst forecast on FTH
Dev Prasad
Lucid Capital
Lucid Capital
$59
Buy
78.95%
Upside
Initiated
09/14/26
Faeth Therapeutics assumed with a Buy at Lucid CapitalFaeth Therapeutics assumed with a Buy at Lucid Capital
BTIG Analyst forecast on FTH
Jeet Mukherjee
BTIG
BTIG
$55
Buy
66.82%
Upside
Reiterated
09/13/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on FTH
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Initiated
09/09/26
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH) and Novartis (NYSE: NVS)
Needham Analyst forecast on FTH
Gil Blum
Needham
Needham
$56
Buy
69.85%
Upside
Initiated
08/21/26
Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target
H.C. Wainwright Analyst forecast on FTH
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$60
Buy
81.98%
Upside
Reiterated
08/11/26
Analyst Reiterates Buy on Faeth, Maintains $60 Price Target Ahead of Phase 2 Readouts
Oppenheimer Analyst forecast on FTH
Jay Olson
Oppenheimer
Oppenheimer
$60
Buy
81.98%
Upside
Reiterated
08/05/26
Oppenheimer Keeps Their Buy Rating on Faeth Therapeutics (FTH)
JonesTrading Analyst forecast on FTH
Boris Peaker
JonesTrading
JonesTrading
$55
Buy
66.82%
Upside
Initiated
08/04/26
Faeth Therapeutics initiated with a Buy at JonesResearchFaeth Therapeutics initiated with a Buy at JonesResearch
Raymond James Analyst forecast on FTH
Sean McCutcheon
Raymond James
Raymond James
$56
Buy
69.85%
Upside
Initiated
07/31/26
Faeth Therapeutics initiated with an Outperform at Raymond JamesFaeth Therapeutics initiated with an Outperform at Raymond James
Citizens JMP Analyst forecast on FTH
Silvan Turkcan
Citizens JMP
Citizens JMP
$51
Buy
54.69%
Upside
Initiated
07/20/26
Faeth Therapeutics initiated with an Outperform at CitizensFaeth Therapeutics initiated with an Outperform at Citizens
Citi Analyst forecast on FTH
Geoff Meacham
Citi
Citi
$55
Buy
66.82%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Staar Surgical (NASDAQ: STAA), Intuitive Surgical (NASDAQ: ISRG) and Faeth Therapeutics (NASDAQ: FTH)
Robert W. Baird Analyst forecast on FTH
Jack Allen
Robert W. Baird
Robert W. Baird
$57
Buy
72.88%
Upside
Initiated
06/26/26
Faeth Therapeutics initiated with an Outperform at BairdFaeth Therapeutics initiated with an Outperform at Baird
Cantor Fitzgerald Analyst forecast on FTH
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (NASDAQ: SNSE) and Kura Oncology (NASDAQ: KURA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AXGNAxoGen
ASNDAscendis Pharma
HROWHarrow Health
IRTCIrhythm Technologies
DNLIDenali Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Faeth Therapeutics

3 Months
Geoff MeachamCiti
Success Rate
3/3 ratings generated profit
100%
Average Return
+119.53%
Copying Geoff Meacham's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +119.53% per trade.
1 Year
Geoff MeachamCiti
Success Rate
3/3 ratings generated profit
100%
Average Return
+113.87%
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +113.87% per trade.
2 Years
Geoff MeachamCiti
Success Rate
3/3 ratings generated profit
100%
Average Return
+113.87%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +113.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FTH Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
2
7
13
17
14
Buy
1
2
2
1
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
9
15
18
16
In the current month, FTH has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. FTH average Analyst price target in the past 3 months is 57.64.
Each month's total comprises the sum of three months' worth of ratings.

FTH Financial Forecast

FTH Earnings Forecast

Next quarter’s earnings estimate for FTH is -$0.78 with a range of -$1.75 to -$0.58. The previous quarter’s EPS was -$2.84. FTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FTH has Performed in-line its overall industry.
Next quarter’s earnings estimate for FTH is -$0.78 with a range of -$1.75 to -$0.58. The previous quarter’s EPS was -$2.84. FTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year FTH has Performed in-line its overall industry.
No data currently available

FTH Sales Forecast

Next quarter’s sales forecast for FTH is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. FTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FTH has Performed in-line its overall industry.
Next quarter’s sales forecast for FTH is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. FTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year FTH has Performed in-line its overall industry.

FTH Stock Forecast FAQ

What is FTH’s average 12-month price target, according to analysts?
Based on analyst ratings, Faeth Therapeutics’s 12-month average price target is 57.64.
    What is FTH’s upside potential, based on the analysts’ average price target?
    Faeth Therapeutics has 74.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is FTH a Buy, Sell or Hold?
          Faeth Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Faeth Therapeutics’s price target?
            The average price target for Faeth Therapeutics is 57.64. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $51.00. The average price target represents 74.81% Increase from the current price of $32.97.
              What do analysts say about Faeth Therapeutics?
              Faeth Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of FTH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.